MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying

MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 8, 2026, Needham initiated coverage of MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating and a $37 price target. Needham said the muscarinic class could be “disruptive” across multiple indications, including schizophrenia and Alzheimer’s disease psychosis, and noted ML-007C-MA may be “differentiated” from Cobenfy on tolerability and convenience, with potential to reach $1.5B in sales by 2035.

On April 7, 2026, TD Cowen initiated coverage of MapLight Therapeutics with a Buy rating, highlighting its pipeline targeting central nervous system and neuropsychiatric conditions. TD Cowen said the lead asset ML-007C-MA is positioned to improve on Cobenfy’s profile in schizophrenia, with a Phase II readout expected in Q3, and views the shares as undervalued based on this opportunity.

MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying

Last month, Canaccord initiated coverage of MapLight Therapeutics with a Buy rating and a $35 price target. Canaccord said the company’s focus on novel CNS therapeutics supports its schizophrenia opportunity and recommends buying the stock ahead of Phase 2 data for ML-007C-MA expected in Q3.

MapLight Therapeutics, Inc. (NASDAQ:MPLT) develops therapies for central nervous system disorders.

While we acknowledge the risk and potential of MPLT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MPLT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.